"This approach may allow clinicians to select the most effective therapeutic agents with real time in patients with pancreatic adenocarcinoma." BUFFALO, NY- September 19, 2023 – A new research paper was published in Oncotarget's Volume 14 on September 15, 2023, entitled, " Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma ." Patient-derived organoids (PDOs) and xenografts (PDXs) have been extensively studied for drug-screening. However, their usage is limited due to lengthy establishment time, high engraftment failure rates and different tumor microenvironment from original tumors.

https://www.miragenews.com/live-assay-reveals-pancreatic-cancer-tissue-1087662/

#miragenews